This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biofrontera Past Earnings Performance

Past criteria checks 3/6

Biofrontera has been growing earnings at an average annual rate of 36.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 15.1% per year. Biofrontera's return on equity is 41.3%, and it has net margins of 34.6%.

Key information

36.2%

Earnings growth rate

43.6%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate15.1%
Return on equity41.3%
Net Margin34.6%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:B8FE Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 223211187
30 Jun 223110247
31 Mar 223015297
31 Dec 212938347
30 Sep 2128-16286
30 Jun 2127-16295
31 Mar 2129-12265
31 Dec 2030-13285
30 Sep 2033-17335
30 Jun 2033-22375
31 Mar 2031-10455
31 Dec 1931-7445
30 Sep 19261444
30 Jun 19268405
31 Mar 1923-8335
31 Dec 1821-9314
30 Sep 1819-14244
30 Jun 1816-15224
31 Mar 1814-16214
31 Dec 1712-16204
30 Sep 1711-18215
30 Jun 179-16175
31 Mar 178-14145
31 Dec 166-11125
30 Sep 164-994
30 Jun 164-784
31 Mar 164-976
31 Dec 154-1176

Quality Earnings: B8FE has a large one-off gain of €39.7M impacting its last 12 months of financial results to 30th September, 2022.

Growing Profit Margin: B8FE became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: B8FE has become profitable over the past 5 years, growing earnings by 36.2% per year.

Accelerating Growth: B8FE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: B8FE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).


Return on Equity

High ROE: B8FE's Return on Equity (41.3%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/06 02:32
End of Day Share Price 2022/09/08 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biofrontera AG is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Navid MalikCavendish Historical (Cenkos Securities)
Robert WassermanDawson James Securities